Know more about...

...AIPGENE: Augmenting PBGD expression in the liver as a novel Gene therapy for Acute Intermittent Porphyria - FP7-Health-2010-261506

This Collaborative Project involves seven partners from four different European countries and is related to the theme HEALTH.2010.2.4.4-1: Clinical development of substances with a clear potential as orphan drugs. The AIPGENE project is co-funded by the European Commission within the 7th Framework Programme for Research. The project is co-ordinated by CIMA, a European Center for Applied Medical Research, started in 2004.

AIPGENE is a collaborative project which aims to develop the clinical use of the orphan drug AAV5-AAT-PBGD for the treatment of the rare disease AIP. The completion of this project will represent an important advance in the clinical management, physiopathology and therapy of metabolic liver diseases. The international team of experts involved in the AIPgene consortium brings together complementary scientific disciplines to implement a new therapeutic option for AIP patients.

pdf Letter AIPGENE


Latest News

New clinical trials in gene therapy show the beginning of a new form of molecular medicine.
Know more...

Prof. Jude Samulski, a pioneer in the field of gene therapy, insisted that in Europe there are strong scientific groups working for new treatments for genetic disorders.
Know more...

140 people attended the International Symposium organized by the AIPGENE Consortium.
Know more...

All the partners and the EAB met in Pamplona in the last AIPGENE Meeting.
Know more...

Web development: Pipermint  Access